Psyence Expands Board Of Directors with Intellectual Property Expert!

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) is pleased to welcome Christopher Bull to its Board of Directors! Mr. Bull is joining the team to help the Company expand upon its market presence, broaden accessibility, and nurture innovative and cutting-edge technology solutions within its industry. His extensive knowledge and expertise bring a welcome asset to Psyence’s Board of Directors.

Mr. Bull is an internationally acclaimed figure in the world of venture capital investment, patent and intellectual property strategies for high-technology companies. In his remarkable 30-year career, he has been an investor, director, founder, and advisor to a range of successful companies across Europe and North America, working with novel technologies such as pharmaceuticals, biotechnology, food sciences, and chemical processing & extraction.

Boasting a plethora of degrees as a qualified engineer, attorney, patent attorney, and Certified Licensing Professional®, Mr. Bull has received various international awards in recognition of his expertise in these areas.

I am thrilled to have the opportunity to join the board of Psyence as they launch their first clinical trial in palliative care. With their expertise in extraction, formulation, and treatment of pharmaceutical-grade psilocybin and psilocin products, the company is poised to make a significant mark in the medical world. I am looking forward to helping Psyence achieve their goals and drive positive change.

We are delighted to welcome Christopher to the Psyence Group board. His impressive background in venture capital and intellectual property will play a major role as we progress with our mission to bring standardized pharmaceutical-grade psilocybin and psilocin products to the fields of research, clinical trials, and drug development. Dr. Neil Maresky, Chief Executive Officer of Psyence Group, is confident that Christopher will be a great addition to the team.


Psyence is unlocking the power of natural psychedelics to become one of the most forward-thinking life science biotechnology companies. Listed on the Canadian Securities Exchange (CSE:PSYG) and quoted on the OTCQB (OTCQB: PSYGF), Psyence is focused on harnessing the power of natural psilocybin to help treat and overcome psychological traumas and its consequences.

Our name “Psyence” melds the words “psychedelic” and “science” together in a nod to our dedication to using scientific and evidence-based research to develop natural psychedelic medicines.

Enlivened by the power of nature and driven by the advances of science, we have constructed and now operate one of the first ever commercial psilocybin mushroom cultivation and production facilities to be licensed by the federal government, located in Southern Africa.

Carefully assembled, our talented team possesses a well-rounded mix of global knowledge in business and science, possessing experienced mycologists, neurologists, palliation specialists and executives specialised in drug development.

Our commitment and dedication pave the path for the development of highly-refined natural psilocybin products that can be used / enhanced in a variety of clinical research plans and endeavors.

Psyence Production and Psyence Therapeutics, two of our core divisions, are the leading forces behind an international collective, with operations located in Canada, the United Kingdom, Southern Africa, and a foothold in the USA and Australia. Our ambition knows no bounds as we work to make the world a better place!

Leave a Comment